z-logo
Premium
Two‐Year Neurodevelopment and Growth Outcomes for Preterm Neonates Who Received Low‐Dose Intravenous Soybean Oil
Author(s) -
Ong Margaret L.,
Purdy Isabell B.,
Levit Orly L.,
Robinson Daniel T.,
Grogan Tristan,
Flores Martiniano,
Calkins Kara L.
Publication year - 2018
Publication title -
journal of parenteral and enteral nutrition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.935
H-Index - 98
eISSN - 1941-2444
pISSN - 0148-6071
DOI - 10.1177/0148607116674482
Subject(s) - medicine , gestational age , bayley scales of infant development , pediatrics , prospective cohort study , incidence (geometry) , cohort , cohort study , small for gestational age , anthropometry , pregnancy , psychomotor learning , cognition , genetics , physics , psychiatry , optics , biology
Background : In some studies, the dose of intravenous soybean oil (SO) has been associated with a decreased incidence of intestinal failure–associated liver disease. The effect of lipid sparing on neurodevelopment (ND) and growth remains unknown. This study investigated the impact of SO dose on ND and growth over the first 2 years of age in preterm neonates. Materials and Methods : This is a single‐site prospective follow‐up study. Neonates with a gestational age ≤29 weeks were randomized to low‐dose (LOW) or standard‐dose (CON) SO. Bayley Scales of Infant Development III and anthropometric measurements were collected at approximately 6, 12, and 24 months corrected gestational age. Results : Subjects were premature, with a mean (±SD) gestational age of 28 ± 1 and 27 ± 1 weeks ( P = .3) for LOW and CON, respectively. Thirty subjects completed follow‐up (LOW = 15, CON = 15). There were no differences for ND and growth outcomes when LOW was compared with CON, with the exception of a higher 12‐month follow‐up cognitive scaled score in the LOW group ( P = .02). Conclusion : A reduced SO dose did not adversely affect ND or growth in this cohort of preterm neonates. However, larger studies are needed to determine the long‐term safety of SO dose reduction before this strategy can be adopted.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here